Publicacions
El coneixement generat a IrsiCaixa es comparteix amb la comunitat científica a través de la publicació d’articles a revistes científiques d’alt impacte.
Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.
Second European Round Table on the Future Management of HIV: 10-11 October 2014, Barcelona, Spain.
The HLA-C*04: 01/KIR2DS4 gene combination and human leukocyte antigen alleles with high population frequency drive rate of HIV disease progression.
Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study.
Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015).
T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
Association between polymorphisms in genes involved in lipid metabolism and immunological status in chronically HIV-infected patients.
Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load.
Determinants of virological failure and antiretroviral drug resistance in Mozambique.
Aggressive human papillomavirus (HPV)-11-related sinonasal inverted papilloma in an HIV-infected patient and the quadrivalent HPV vaccine: a case report.